Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747858 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
A Phase 2 study of Cystic Fibrosis and CFTR Gene Mutation, sponsored by Arcturus Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 11
- Study locations
NCT06747858: Recruiting Phase 2 study of Cystic Fibrosis and CFTR Gene Mutation, sponsored by Arcturus Therapeutics.
NCT06747858 is a Phase 2 study of Cystic Fibrosis and CFTR Gene Mutation that is actively recruiting participants, run by Arcturus Therapeutics. The registered enrollment target is 12 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06747858, a Phase 2 study of Cystic Fibrosis and CFTR Gene Mutation, is actively recruiting participants, sponsored by Arcturus Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 11
- Study locations
Study Summary
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
Primary Outcome
Safety and tolerability of ARCT-032 assess by determining incidence, severity and dose-relationship of AEs by dose level
Conditions Studied
Interventions
- BIOLOGICAL ARCT-032
Study Locations (11)
Florida
- Joe DiMaggio Children's Hospital - Hollywood
- Central Florida Pulmonary Group - Orlando
Arizona
- University of Arizona - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- Children's Hospital of Los Angeles - Los Angeles
Illinois
- The Cystic Fibrosis Institute - Northfield
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Washington University - St Louis
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT06747858 shows while recruiting
NCT06747858 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which ARCT-032 is the first listed.
NCT06747858 lists 11 locations in 10 states (Florida, Arizona, Arkansas).
Frequently Asked Questions
What is clinical trial NCT06747858 about?
NCT06747858 is a clinical study titled "Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis". ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
What is the current status of trial NCT06747858?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2024-12-12. Estimated completion is 2025-12.
What conditions does trial NCT06747858 study?
This clinical trial studies the following conditions: Cystic Fibrosis, CFTR Gene Mutation.
What interventions are being tested in trial NCT06747858?
The interventions under investigation include: ARCT-032 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06747858?
This trial is sponsored by Arcturus Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747858 being conducted?
This trial has 11 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06747858's enrollment target sits among peer trials
12 152nd of 169 higher than 15 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
RECRUITING · Phase 2
-
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
RECRUITING · Phase 2
-
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
RECRUITING · Phase 2
-
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI